Community/Retail

The latest teen drug use survey reveals that use of vaping devices and e-liquids have increased.

In this clip, Fred Massoomi, PharmD, FASHP, Senior Director at Visante, offers advice on the best practices for USP 800 compliance, including gap analysis, individual monitoring, and education.

The FDA has approved pegfilgrastim-jmdb (Fulphila, Mylan GmbH) as the first biosimilar to pegfilgrastim (Neulasta) to help reduce the chance of fever-causing infection for a population of patients with cancer.

A pharmacy that truly differentiates itself may create a niche that the giant online retailer would have trouble encroaching upon.

For health care providers, staying up to date on drug development trends is crucial to understanding the implications of these therapies and how they can best help their patients.

An emerging area of investigation in asthma and chronic obstructive pulmonary disease is use of statins.

Combining pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate (ORR) of 41% in patients with advanced non–small cell lung cancer (NSCLC), according to findings from an early phase study presented at the 2018 ASCO Annual meeting.

In this clip, Dennis Killian, PharmD, PhD, Director of Pharmacy at Peninsula Regional Medical Center, compares the use of premixed with compound IV products for enhanced patient safety.

The new section will provide an enhanced focus on ASHP’s efforts to help its members provide optimal patient care and comprehensive medication therapy management in the specialty pharmacy environment.

In this clip, Dennis Killian, PharmD, PhD, Director of Pharmacy at Peninsula Regional Medical Center, discusses the features and functionalities to consider when purchasing a new infusion pump.

Leticia Shea, PharmD, BCACP, Associate Professor of Pharmacy at Regis University, discusses why it's important for pharmacists to educate patients on medical cannabis use.

Dennis Killian, PharmD, PhD, Director of Pharmacy at Peninsula Regional Medical Center, talks about the benefits of using ready-to-use, premixed IV products versus compound IV products.

Sponsored by ASHP and the ASHP Research and Education Foundation, the award honors student members in their second through fourth professional years of pharmacy school.

The FDA has approved baricitinib (Olumiant), a once-daily oral drug for adults with moderately-to-severely active rheumatoid arthritis.

An extension trial assesses the efficacy and safety of extending edaravone treatment past the FDA-approved 6 cycles.

Our team is on site in Denver all week covering from ASHP Summer 2018.

Studies explore the efficacy and safety of anticoagulation for atrial fibrillation in hemodialysis.

When individuals who are at risk for HIV use PrEP, and use it appropriately, risk of infection is significantly lowered.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

What role do pharmacists play in medication optimization to help save money?

New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.

Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, and Specialty Pharmacy Times, the most read publication among specialty pharmacists, have been honored with the 2018 Hermes Creative Awards.

Researchers have published a review article in the journal Aging Male that implicates folic acid as a contributing factor in erectile dysfunction.

TherapeuticsMD announced it has received FDA approval for IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia.

Tofacitinib is the first and only Janus kinase inhibitor approved by the FDA for this patient population.

Screening for colorectal cancer (CRC) should begin at age 45 for people of average risk, according to newly updated American Cancer Society guidelines.

Shingrix (Recombinant zoster vaccine) has been associated with vaccine administration errors since it hit the market, according to a new CDC report.